The Mayo Clinic and other large transplant centers have received the first shipments of Evusheld. The federal government allocated 225,432 courses of the treatment to all states. However, the state of Florida did not receive all of the quota, as it has not ordered all of the drugs. The state’s health department is contacting providers and gauging their need, and if they are interested in receiving an order.
Initially, the drug will be distributed to hospitals. The U.S. federal government has purchased 700,000 doses of Evusheld, which will be divided amongst states. Each state will determine which patients will receive Evusheld, and prioritization will vary. In addition, eligibility will be based on the state’s population. AstraZeneca and the IDF are working closely together to make the new drug available to patients.
AstraZeneca reported in November that it would not be able to sell Evusheld in the U.S. after 2021. The company said that the U.S. government purchased 1.7 million doses of Evusheld and had six hundred thousand doses ready to be distributed. According to a government distribution disclosure, 49,992 doses were sent to states, territories, and hospitals. As of the time of writing, the United States government has not yet decided how to distribute the remaining 600,000 doses.
While AstraZeneca has been distributing Evusheld, it is not yet available to the public. This means that hospitals will have to allocate these doses to patients. A spokesperson from AstraZeneca confirmed to CNN that there are more doses of Evusheld available. The next phase of the distribution plans is expected to be more complicated than the one for the COVID-19 vaccine, and eligibility criteria will depend on the specific state.
The United States government plans to distribute Evusheld in 2021. The state will distribute the drug to health care providers, and they will develop their own prioritization guidelines for the drug. The allocation of the drug to the states could vary depending on logistical factors. The federal government is currently supplying the monoclonal antibody cocktail to the U.S. for the first time. AstraZeneca has estimated that the drug will cost around $700 million in the U.S. before being distributed.
The health department will distribute Evusheld to healthcare providers. Individual health care providers will determine how much to distribute to patients. Some hospitals will be excluded from receiving the vaccine, but some will be eligible for it regardless of the condition. For those who qualify, the drug is meant to be given to individuals with compromised immune systems. The distribution process will differ from state to state, and the EMA will tweet its rolling review of the drug.
Since the U.S. FDA approved the drug in December, the drug’s availability in the U.S. will depend on the number of patients who have an immunocompromised state. The government’s plan to distribute the drug to all states could differ depending on the availability and needs of the drug. If it does, the administration plans will be more complicated and states will determine how much they should distribute the drug.
The US government plans to distribute the drug to health care providers. Some states have already begun the process of distributing the drug. In the year 2022, the FDA plans to distribute the drug to health care providers on a pro-rata basis. This will make Evusheld more available to the public. For now, it is unclear how it will be distributed. AstraZeneca is aiming for minimal sales in 2021 and hopes to release the drug on the market by the end of the year.
The U.S. government is planning to distribute the drug through a state-based system. The vaccine is meant for people with moderate-to-severe immunocompromised states. As of the start of the program, the vaccine will be made available for the U.S. government to give to the state governments on a pro-rata basis. The U.S. has already ordered more than 800,000 doses, but the government will only distribute them to states based on their population. The administration is planning to distribute the remaining 199,992 doses to states.